Cristian Suarez-Cabrera
Overview
Explore the profile of Cristian Suarez-Cabrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Page A, Bravo A, Suarez-Cabrera C, Sanchez-Baltasar R, Oteo M, Morcillo M, et al.
Int J Oral Sci
. 2020 Jan;
12(1):1.
PMID: 31900382
Odontogenic tumours are a heterogeneous group of lesions that develop in the oral cavity region and are characterized by the formation of tumoural structures that differentiate as teeth. Due to...
12.
Martinez V, Munera-Maravilla E, Bernardini A, Rubio C, Suarez-Cabrera C, Segovia C, et al.
Front Genet
. 2019 Dec;
10:1125.
PMID: 31850055
Bladder cancer (BC) is the most common neoplasia of the urothelial tract. Due to its high incidence, prevalence, recurrence and mortality, it remains an unsolved clinical and social problem. The...
13.
Lopez-Mateo I, Alonso-Merino E, Suarez-Cabrera C, Park J, Cheng S, Alemany S, et al.
Thyroid
. 2019 Nov;
30(1):116-132.
PMID: 31760908
A subpopulation of cancer stem cells (CSCs) with capacity for self-renewal is believed to drive initiation, progression, and relapse of breast tumors. Since the thyroid hormone receptor β (TRβ) appears...
14.
Duenas M, Perez-Figueroa A, Oliveira C, Suarez-Cabrera C, Sousa A, Oliveira P, et al.
Sci Rep
. 2019 Jul;
9(1):10362.
PMID: 31316092
Non-muscle invasive bladder cancer (NMIBC) represents a crucial problem for the national health care systems due to its high rates of recurrence and the consequent need of frequent follow-ups. Here,...
15.
Segovia C, Jose-Eneriz E, Munera-Maravilla E, Martinez-Fernandez M, Garate L, Miranda E, et al.
Nat Med
. 2019 Jul;
25(7):1073-1081.
PMID: 31270502
Bladder cancer is lethal in its advanced, muscle-invasive phase with very limited therapeutic advances. Recent molecular characterization has defined new (epi)genetic drivers and potential targets for bladder cancer. The immune...
16.
Loras A, Suarez-Cabrera C, Martinez-Bisbal M, Quintas G, Paramio J, Martinez-Manez R, et al.
Cancers (Basel)
. 2019 May;
11(5).
PMID: 31100982
Metabolism reprogramming is considered a hallmark of cancer. The study of bladder cancer (BC) metabolism could be the key to developing new strategies for diagnosis and therapy. This work aimed...
17.
Alameda J, Ramirez A, Garcia-Fernandez R, Navarro M, Page A, Segovia J, et al.
Aging (Albany NY)
. 2019 Jan;
11(1):127-159.
PMID: 30631004
CYLD is a deubiquitinating enzyme known for its role as a tumor suppressor whose mutation leads to skin appendages tumors and other cancers. In this manuscript we report that the...
18.
CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of Status
Rubio C, Martinez-Fernandez M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, et al.
Clin Cancer Res
. 2018 Sep;
25(1):390-402.
PMID: 30242024
Purpose: Bladder cancer is a clinical and social problem due to its high incidence and recurrence rates. It frequently appears in elderly patients showing other medical comorbidities that hamper the...
19.
Suarez-Cabrera C, de la Pena B, Gonzalez L, Page A, Martinez-Fernandez M, Casanova M, et al.
Sci Rep
. 2018 Aug;
8(1):13038.
PMID: 30158566
Although Ras genes are frequently mutated in human tumors, these mutations are uncommon in breast cancer. However, many breast tumors show evidences of Ras pathway activation. In this manuscript, we...
20.
Lodewijk I, Duenas M, Rubio C, Munera-Maravilla E, Segovia C, Bernardini A, et al.
Int J Mol Sci
. 2018 Aug;
19(9).
PMID: 30149597
Bladder Cancer (BC) represents a clinical and social challenge due to its high incidence and recurrence rates, as well as the limited advances in effective disease management. Currently, a combination...